{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:10:58Z","timestamp":1785337858554,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-ES-380-5636"],"award-info":[{"award-number":["IN-ES-380-5636"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jinf.2025.106651","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:17:45Z","timestamp":1762503465000},"page":"106651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bictegravir\/emtricitabine\/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial)"],"prefix":"10.1016","volume":"91","author":[{"given":"Juan","family":"Ambrosioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-6545","authenticated-orcid":false,"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonsoles","family":"S\u00e1nchez-Palomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Bail\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-0098","authenticated-orcid":false,"given":"Paula","family":"Suanzes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Busca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5251-2161","authenticated-orcid":false,"given":"Luis","family":"Ramos-Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2684-3431","authenticated-orcid":false,"given":"Eva","family":"Orviz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Del","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-0417","authenticated-orcid":false,"given":"S\u00f2nia","family":"Vicens-Art\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-364X","authenticated-orcid":false,"given":"Elisa","family":"Moraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cruceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-141X","authenticated-orcid":false,"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jinf.2025.106651_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14787210.2014.913981","article-title":"Update on antiretroviral treatment during primary HIV infection","volume":"12","author":"Ambrosioni","year":"2014","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"16","key":"10.1016\/j.jinf.2025.106651_bib2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1097\/QAD.0b013e32835805b6","article-title":"Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections","volume":"26","author":"Ambrosioni","year":"2012","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jinf.2025.106651_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.20411\/pai.v5i1.341","article-title":"Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection-results of italian network of ACuTe HIV InfectiON (INACTION) retrospective study","volume":"5","author":"Muscatello","year":"2020","journal-title":"Pathog Immun"},{"issue":"3","key":"10.1016\/j.jinf.2025.106651_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa1110187","article-title":"Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy","volume":"368","author":"Le","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jinf.2025.106651_bib5","first-page":"1","article-title":"Acute HIV infection and CD4\/CD8 ratio normalization after antiretroviral therapy initiation","volume":"79","author":"Davy-Mendez","year":"2018","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2025.106651_bib6","doi-asserted-by":"crossref","unstructured":"Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, Souza M. De, et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection; 2016;43\u201348.","DOI":"10.1016\/S2055-6640(20)30688-9"},{"issue":"7","key":"10.1016\/j.jinf.2025.106651_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jinf.2025.106651_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.jinf.2025.106651_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000002447","article-title":"Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection","volume":"34","author":"Veil","year":"2020","journal-title":"AIDS"},{"issue":"10107","key":"10.1016\/j.jinf.2025.106651_bib10","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"issue":"10107","key":"10.1016\/j.jinf.2025.106651_bib11","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiori","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jinf.2025.106651_bib12","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/jac\/dkae138","article-title":"Effectiveness, safety and discontinuation rates of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) in people with HIV using real-world data: a systematic review and meta-analysis","volume":"79","author":"Chivite","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2025.106651_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ebiom.2019.02.016","article-title":"Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection","volume":"41","author":"Tr\u00e9meaux","year":"2019","journal-title":"eBioMedicine"},{"issue":"7","key":"10.1016\/j.jinf.2025.106651_bib14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/infdis\/jiad292","article-title":"Absence of proviral Human Immunodeficiency Virus (HIV) type 1 evolution in early-treated individuals with HIV switching to dolutegravir monotherapy during 48 weeks","volume":"228","author":"J\u00f6rimann","year":"2023","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.jinf.2025.106651_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.29114","article-title":"HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial","volume":"95","author":"Bruzzesi","year":"2023","journal-title":"J Med Virol"},{"issue":"August","key":"10.1016\/j.jinf.2025.106651_bib16","first-page":"1","article-title":"Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption","volume":"13","author":"Pace","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jinf.2025.106651_bib17","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/jac\/dkac207","article-title":"Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, phase 3 trial","volume":"77","author":"Ch\u00e9ret","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jinf.2025.106651_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph15040403","article-title":"Virological and immunological outcomes of an intensified four-drug versus a standard three-drug antiretroviral regimen, both integrase strand transfer inhibitor-based, in primary HIV infection","volume":"15","author":"Mondi","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.jinf.2025.106651_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAD.0000000000003088","article-title":"Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals","volume":"36","author":"Moldt","year":"2022","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jinf.2025.106651_bib20","doi-asserted-by":"crossref","first-page":"9966","DOI":"10.1038\/s41467-024-54116-1","article-title":"Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease","volume":"15","author":"Barbehenn","year":"2024","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.jinf.2025.106651_bib21","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00002030-200309050-00005","article-title":"Dynamics of HIV viremia and antibody seroconversion in plasma donors","volume":"17","author":"Fiebig","year":"2003","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.jinf.2025.106651_bib22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmi.2018.10.021","article-title":"Epidemiological changes of acute\/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study","volume":"25","author":"Nicol\u00e1s","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.jinf.2025.106651_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf545","article-title":"Strategies to minimize time from HIV acquisition to ART initiation: the Barcelona Early-cART Program","volume":"12","author":"Bail\u00f3n","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"31","key":"10.1016\/j.jinf.2025.106651_bib24","doi-asserted-by":"crossref","first-page":"18692","DOI":"10.1073\/pnas.2006816117","article-title":"Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA","volume":"117","author":"Simonetti","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.jinf.2025.106651_bib25","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(20)30271-X","article-title":"Primary HIV-1 infection in users of pre-exposure prophylaxis","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.jinf.2025.106651_bib26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/QAD.0000000000002243","article-title":"E157Q integrase strand-transfer inhibitor substitution in patients with acute\/recent HIV infection","volume":"33","author":"Ambrosioni","year":"2019","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jinf.2025.106651_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkw376","article-title":"Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute\/recent HIV infection","volume":"72","author":"Ambrosioni","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jinf.2025.106651_bib28","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.jinf.2025.106651_bib29","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study","volume":"9","author":"S\u00e1ez-Ciri\u00f3n","year":"2013","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.jinf.2025.106651_bib30","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jinf.2025.106651_bib31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig 1 acute HIV infection brief-communication","volume":"24","author":"Colby","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jinf.2025.106651_bib32","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(22)00302-2","article-title":"Immunological and virological findings in a patient with exceptional post-treatment control: a case report","volume":"10","author":"Climent","year":"2023","journal-title":"Lancet HIV"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325002518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325002518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:59:43Z","timestamp":1778669983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325002518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0163445325002518"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106651","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bictegravir\/emtricitabine\/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial)","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106651"}}